醫藥板塊跑贏大市中生(01177.HK)復星醫藥(02196.HK)彈4.4%-6%
恆指及國指扭五連跌反彈，半日收28,205及10,701，回升0.3%及0.5%。醫藥板塊今早跑贏大市，尤其是旗下用於治療機能減退女性性慾障礙注射液獲批及擬最多2.5億人民幣收購葛蘭素史克製藥(蘇州)的復星醫藥(02196.HK)扭三連跌，最高見24.9元，半日收24.65元，回升6%；獲里昂升價至15%至10.56元以反映旗下重磅藥品安羅替尼獲註冊獲批對公司收入貢獻的中生製藥(01177.HK)連吐兩天守穩10天線，半日股價回升4.4%報8.81元。同為藍籌石藥(01093.HK)扭四連跌，半日回升3.6%報12.64元，股價挑戰10天線(12.69元)。
金斯瑞生物(01548.HK)升破20天及10天線(19.28-19.55元)，最高見19.86元，半日收19.64元，續升3.5%。三生製藥(01530.HK)回升2.9%，報14.12元，股價重越10天及100天線(13.9元)。華潤醫藥(03320.HK)回升3.9%報8.83元，股價重越10天線(8.81元)。威高股份(1066.HK)回落守穩牛熊線，今早股價一舉重越4條移動平均線(7.1-7.18元)，最高見7.35元，半日收7.26元，回升3.7%。石四藥(02005.HK)曾越100天及250天線(6.95-6.97元)，最高見6.98元，半日收6.94元，回升3%。麗珠醫藥(01513.HK)半日回升3.2%報19.1元，股價重越50天及10天線(18.87元)。上海醫藥(02607.HK)由52周低位回升2%報15.16元，挑戰10天線(15.23元)。綠葉製藥(02186.HK)重越10天線(5.78元)，半日收5.8元，回升2.7%。愛康醫療(01789.HK)回升3.8%報4.38元，創逾三個月高，但暫受制牛熊線(4.53元)之下。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
